Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -23.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.48 | N/A | -23.08% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about recent performance but remains focused on future opportunities. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite current setbacks.
ADMA BioLogics reported a larger-than-expected loss per share, which indicates ongoing challenges for the company. Despite this, the stock saw a slight increase of 0.55%, likely due to investor optimism or external market factors. The lack of revenue data and guidance may leave investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RBC BEARINGS INC
Nov 9, 2015